m6A阅读蛋白IGF2BP3在恶性肿瘤发生发展中生物学作用的研究进展

doi:10.13481/j.1671-587X.20260531

Abstract

Abstract:

Insulin-like growth factor 2 mRNA binding protein 3 （IGF2BP3） is a critical RNA-binding protein in organisms， playing key roles in the regulation of mRNA localization， stability， and post-transcriptional translation. N6-methyladenosine （m⁶A） is one of the most prevalent modifications on mammalian mRNA， and IGF2BP3 may function as a reader protein for m⁶A methylation modifications involved in regulating mRNA metabolism. IGF2BP3 is highly expressed in various malignant tumors and is associated with poor prognosis in the patients. Targeting IGF2BP3 or its upstream and downstream regulatory networks may represent a novel strategy for cancer therapy. This review summarized the roles and potential mechanisms of IGF2BP3， acting as both a RNA-binding protein and an m⁶A reader protein， in regulating malignant biological behaviors including proliferation， invasion， metabolic reprogramming， and drug resistance in various tumor cells such as glioblastoma（BGM）， breast cancer（BC）， and lung cancer， in order to provide novel insights for the treatment of malignant tumors.

Key words: IGF2BP3, m⁶A modification, Malignant tumor, Methylation, Therapeutic target, Tumor progression

CLC Number:

R73-3

Laiping LI,Guifeng LI,Ruijing DU,Jinzhi PENG,Peixue YAO,Huan JIN. Research progress in biological roles of m⁶A reader protein IGF2BP3 in development and progression of malignant tumor[J].Journal of Jilin University(Medicine Edition), 2026, 52(5): 1491-1502.

Figures/Tables 3

References 84

[1]	WANG P F， WANG X Y， LIU M， et al. The oncogenic functions of insulin-like growth factor 2 mRNA-binding protein 3 in human carcinomas［J］. Curr Pharm Des， 2020， 26（32）： 3939-3954.
[2]	HAN C Y， HU C C， LIU T Y， et al. IGF₂BP₃ enhances lipid metabolism in cervical cancer by upregulating the expression of SCD［J］. Cell Death Dis， 2024， 15： 138.
[3]	LANGE F， HÖRNSCHEMEYER M F， KIRSCHSTEIN T. Glutamatergic mechanisms in glioblastoma and tumor-associated epilepsy［J］. Cells， 2021， 10（5）： 1226.
[4]	ZHENG X， LI S G， YU J， et al. N6-methyladenosine reader IGF2BP3 as a prognostic Biomarker contribute to malignant progression of glioma［J］. Transl Cancer Res， 2023， 12（4）： 992-1005.
[5]	WANG C B， ZHANG M J， LIU Y L， et al. CircRNF10 triggers a positive feedback loop to facilitate progression of glioblastoma via redeploying the ferroptosis defense in GSCs［J］. J Exp Clin Cancer Res， 2023， 42（1）： 242.
[6]	JIN P C， HUANG Y N， ZHU P L， et al. CircRNA circHIPK3 serves as a prognostic marker to promote glioma progression by regulating miR-654/IGF2BP3 signaling［J］. Biochem Biophys Res Commun， 2018， 503（3）： 1570-1574.
[7]	KOUHKAN F， MOBARRA N， SOUFI-ZOMORROD M， et al. microRNA-129-1 acts as tumour suppressor and induces cell cycle arrest of GBM cancer cells through targeting IGF2BP3 and MAPK1［J］. J Med Genet， 2016， 53（1）： 24-33.
[8]	HUANG S L， LIU L， XU Z P， et al. Exosomal miR-6733-5p mediates cross-talk between glioblastoma stem cells and macrophages and promotes glioblastoma multiform progression synergistically［J］. CNS Neurosci Ther， 2023， 29（12）： 3756-3773.
[9]	LI B Y， ZHAO R R， QIU W， et al. The N⁶-methyladenosine-mediated lncRNA WEE2-AS1 promotes glioblastoma progression by stabilizing RPN2［J］. Theranostics， 2022， 12（14）： 6363-6379.
[10]	LIU C， DOU X Y， ZHAO Y T， et al. IGF2BP3 promotes mRNA degradation through internal m7G modification［J］. Nat Commun， 2024， 15： 7421.
[11]	LI Y， CAO J， WANG J F， et al. Association of the m⁶A reader IGF2BP3 with tumor progression and brain-specific metastasis in breast cancer［J］. Cancer， 2024， 130（3）： 356-374.
[12]	KIM H Y， HA THI H T， HONG S. IMP2 and IMP3 cooperate to promote the metastasis of triple-negative breast cancer through destabilization of progesterone receptor［J］. Cancer Lett， 2018， 415： 30-39.
[13]	ZHANG W， LIU H， JIANG J J， et al. CircRNA circFOXK2 facilitates oncogenesis in breast cancer via IGF2BP3/miR-370 axis［J］. Aging， 2021， 13（14）： 18978-18992.
[14]	WALSH L A， ALVAREZ M J， SABIO E Y， et al. An integrated systems biology approach identifies TRIM25 as a key determinant of breast cancer metastasis［J］. Cell Rep， 2017， 20（7）： 1623-1640.
[15]	WANG Z Z， TONG D D， HAN C， et al. Blockade of miR-3614 maturation by IGF2BP3 increases TRIM25 expression and promotes breast cancer cell proliferation［J］. EBioMedicine， 2019， 41： 357-369.
[16]	BAO G， HUANG J J， PAN W， et al. Long noncoding RNA CERS6-AS1 functions as a malignancy promoter in breast cancer by binding to IGF2BP3 to enhance the stability of CERS6 mRNA［J］. Cancer Med， 2020， 9（1）： 278-289.
[17]	LAN J. circBRAF promotes the progression of triple-negative breast cancer through modulating methylation by recruiting KDM4B to histone H3K9me3 and IGF2BP3 to mRNA［J］. Am J Cancer Res， 2024， 14（5）： 2020-2036.
[18]	ZHANG X， SHI L， SUN H D， et al. IGF2BP3mediates the mRNA degradation of NF1 to promote triple-negative breast cancer progression via an m6A-dependent manner［J］. Clin Transl Med， 2023， 13（9）： e1427.
[19]	WAN W J， AO X， CHEN Q， et al. METTL3/IGF2BP3 axis inhibits tumor immune surveillance by upregulating N6-methyladenosine modification of PD-L1 mRNA in breast cancer［J］. Mol Cancer， 2022， 21（1）： 60.
[20]	ZHANG Z L， HUO W J， LI J. circATAD2 mitigates CD8⁺ T cells antitumor immune surveillance in breast cancer via IGF2BP3/m⁶A/PD-L1 manner［J］. Cancer Immunol Immunother， 2024， 73（7）： 130.
[21]	FU W， LIU L X， TONG S J. Berberine inhibits the progression of breast cancer by regulating METTL3-mediated m6A modification of FGF7 mRNA［J］. Thorac Cancer， 2024， 15（17）： 1357-1368.
[22]	ZHOU S C， SHENG L J， ZHANG L， et al. METTL3/IGF2BP3-regulated m6A modification of HYOU1 confers doxorubicin resistance in breast cancer［J］. Biochim Biophys Acta BBA Gen Subj， 2024， 1868（3）： 130542.
[23]	GUO W， HUAI Q L， WAN H， et al. Prognostic impact of IGF2BP3 expression in patients with surgically resected lung adenocarcinoma［J］. DNA Cell Biol， 2021， 40（2）： 316-331.
[24]	LI Y， GU J， XU F K， et al. Molecular characterization， biological function， tumor microenvironment association and clinical significance of m⁶A regulators in lung adenocarcinoma［J］. Brief Bioinform， 2021， 22（4）： bbaa225.
[25]	LIU Z C， WANG T T， SHE Y L， et al. N6-methyladenosine-modified circIGF2BP3 inhibits CD8⁺ T-cell responses to facilitate tumor immune evasion by promoting the deubiquitination of PD-L1 in non-small cell lung cancer［J］. Mol Cancer， 2021， 20（1）： 105.
[26]	HUANG X Q， ZHANG J， JIANG Y Q， et al. IGF2BP3 may contributes to lung tumorigenesis by regulating the alternative splicing of PKM［J］. Front Bioeng Biotechnol， 2020， 8： 679.
[27]	YAN A， SONG X W， LIU B， et al. IGF2BP3 worsens lung cancer through modifying long non-coding RNA CERS6-AS1/microRNA-1202 axis［J］. Curr Med Chem， 2023， 30（7）： 878-891.
[28]	SUN J F， WANG H， ZHANG R， et al. IGF2BP3/CTCF axis-dependent NT5DC2 promotes M2 macrophage polarization to enhance the malignant progression of lung squamous cell carcinomas［J］. Clin Respir J， 2024， 18（11）： e70031.
[29]	LV X， HUANG H P， FENG H， et al. Circ-MMP2 （circ-0039411） induced by FOXM1 promotes the proliferation and migration of lung adenocarcinoma cells in vitro and in vivo ［J］. Cell Death Dis， 2020， 11： 426.
[30]	CHEN X Y， ZHU X X， SHEN X Y， et al. IGF2BP3aggravates lung adenocarcinoma progression by modulation of PI3K/AKT signaling pathway［J］. Immunopharmacol Immunotoxicol， 2023， 45（3）： 370-377.
[31]	LI P W， GE H B， ZHAO J F， et al. Disrupting of IGF2BP3-stabilized HK2 mRNA by MYO16-AS1 competitively binding impairs LUAD migration and invasion［J］. Mol Cell Biochem， 2024， 479（10）： 2795-2808.
[32]	XU X， QIU S Y， ZENG B J， et al. N6-methyladenosine demethyltransferase FTO mediated m⁶A modification of estrogen receptor alpha in non-small cell lung cancer tumorigenesis［J］. Oncogene， 2024， 43（17）： 1288-1302.
[33]	ZHANG X L， CHEN Q Q， HE Y， et al. STRIP2 motivates non-small cell lung cancer progression by modulating the TMBIM6 stability through IGF2BP3dependent［J］. J Exp Clin Cancer Res， 2023， 42（1）： 19.
[34]	LIN Z Y， LI J W， ZHANG J， et al. Metabolic reprogramming driven by IGF2BP3 promotes acquired resistance to EGFR inhibitors in non-small cell lung cancer［J］. Cancer Res， 2023， 83（13）： 2187-2207.
[35]	YANG X， BAI Q R， CHEN W Z， et al. m⁶A-dependent modulation via IGF2BP3/MCM5/Notch axis promotes partial EMT and LUAD metastasis［J］. Adv Sci， 2023， 10（20）： 2206744.
[36]	JIANG W J， CHENG X L， WANG T， et al. LINC00467 promotes cell proliferation and metastasis by binding with IGF2BP3 to enhance the mRNA stability of TRAF5 in hepatocellular carcinoma［J］. J Gene Med， 2020， 22（3）： e3134.
[37]	JIN D， HUI Y F， LIU D， et al. LINC00942 inhibits ferroptosis and induces the immunosuppression of regulatory T cells by recruiting IGF2BP3/SLC7A11 in hepatocellular carcinoma［J］. Funct Integr Genom， 2024， 24（1）： 29.
[38]	YAN J L， WANG X F， FAN Z Y， et al. Circ_0098823 binding with IGF2BP3 regulates DNM1L stability to promote metastasis of hepatocellular carcinoma via mitochondrial fission［J］. Apoptosis， 2024， 29（5）： 709-725.
[39]	ZHANG W， ZHU L， YANG G W， et al. Hsa_circ_0026134 expression promoted TRIM25- and IGF2BP3-mediated hepatocellular carcinoma cell proliferation and invasion via sponging miR-127-5p［J］. Biosci Rep， 2020， 40（7）： BSR20191418.
[40]	GAO Y， LUO T P， OUYANG X W， et al. IGF2BP3 and miR191-5p synergistically increase HCC cell invasiveness by altering ZO-1 expression［J］. Oncol Lett， 2020， 20（2）： 1423-1431.
[41]	LU Y X， ZHU J H， ZHANG Y X， et al. Lactylation-driven IGF2BP3-mediated serine metabolism reprogramming and RNA m6A： modification promotes lenvatinib resistance in HCC［J］. Adv Sci， 2024， 11（46）： 2401399.
[42]	LU Z H， YANG H， SHAO Y T， et al. IGF2BP3-NRF2 axis regulates ferroptosis in hepatocellular carcinoma［J］. Biochem Biophys Res Commun， 2022， 627： 103-110.
[43]	GAO H， SHI L， LIU J F， et al. FOXM1-activated IGF2BP3 promotes cell malignant phenotypes and M2 macrophage polarization in hepatocellular carcinoma by inhibiting ferroptosis via stabilizing RRM2 mRNA in an m6A-dependent manner［J］. Mol Cell Biochem， 2025， 480（5）： 3051-3066.
[44]	YANG Z， WANG T F， WU D J， et al. RNA N6-methyladenosine reader IGF2BP3 regulates cell cycle and angiogenesis in colon cancer［J］. J Exp Clin Cancer Res， 2020， 39（1）： 203.
[45]	LI X Y. IGF2BP3-induced activation of EIF5B contributes to progression of hepatocellular carcinoma cells［J］. Oncol Res， 2022， 30（2）： 77-87.
[46]	WANG C X， DONG R， YANG F C， et al. LARP4B promotes hepatocellular carcinoma progression and impairs sorafenib efficacy by activating SPINK1-mediated EGFR pathway［J］. Cell Death Discov， 2024， 10： 208.
[47]	KEXIN L， FURONG H， YAN L，et al.Stabilization of oncogenic transcripts by the IGF2BP3/ELAVL1 complex promotes tumorigenicity in colorectal cancer［J］.American journal of cancer research， 2020， 10（8）：2480-2497.
[48]	HUANG Y Y， ZHANG C， DAI Y， et al. USP11 facilitates colorectal cancer proliferation and metastasis by regulating IGF2BP3 stability［J］. Am J Transl Res， 2021，13（2）：480-496.
[49]	ZHANG W， WANG B， LIN Y L， et al. hsa_circ_0000231 Promotes colorectal cancer cell growth through upregulation of CCND2 by IGF2BP3/miR-375 dual pathway［J］. Cancer Cell Int， 2022， 22（1）： 27.
[50]	XU W M， SHENG Y R， GUO Y G， et al. Increased IGF2BP3 expression promotes the aggressive phenotypes of colorectal cancer cells in vitro and vivo ［J］. J Cell Physiol， 2019， 234（10）： 18466-18479.
[51]	GUI Z W， LI J W， LI J， et al. Berberine promotes IGF2BP3 ubiquitination by TRIM21 to induce G1/S phase arrest in colorectal cancer cells［J］. Chem Biol Interact， 2023， 374： 110408.
[52]	ZHANG Y R， LIU X J， YU M， et al. Berberine inhibits proliferation and induces G0/G1 phase arrest in colorectal cancer cells by downregulating IGF2BP3［J］. Life Sci， 2020， 260： 118413.
[53]	CHEN Z J， ZHOU J W， WU Y， et al. METTL3 promotes cellular senescence of colorectal cancer via modulation of CDKN2B transcription and mRNA stability［J］. Oncogene， 2024， 43（13）： 976-991.
[54]	ZHANG M， ZHAO S L， TAN C， et al. RNA-binding protein IMP3 is a novel regulator of MEK1/ERK signaling pathway in the progression of colorectal Cancer through the stabilization of MEKK1 mRNA［J］. J Exp Clin Cancer Res， 2021， 40（1）： 200.
[55]	LI K， GUO J W， MING Y， et al. A circular RNA activated by TGFβ promotes tumor metastasis through enhancing IGF2BP3-mediated PDPN mRNA stability［J］. Nat Commun， 2023， 14： 6876.
[56]	YANG Z M， ZHAO F Q， GU X F， et al. Binding of RNA m6A by IGF2BP3 triggers chemoresistance of HCT8 cells via upregulation of ABCB1［J］. Am J Cancer Res， 2021， 11（4）： 1428-1445.
[57]	CHEN L J， LIU H Y， XIAO Z Y， et al. IGF2BP3 promotes the progression of colorectal cancer and mediates cetuximab resistance by stabilizing EGFR mRNA in an m⁶A-dependent manner［J］. Cell Death Dis， 2023， 14： 581.
[58]	DROUILLARD A， MANFREDI S， LEPAGE C， et al. Épidémiologie du cancer du pancréas［J］. Bull Du Cancer， 2018， 105（1）： 63-69.
[59]	CUI X H， HU S Y， ZHU C F， et al. Expression and prognostic analyses of the insulin-like growth factor 2 mRNA binding protein family in human pancreatic cancer［J］. BMC Cancer， 2020， 20（1）： 1160.
[60]	LI S M， JIANG F R， CHEN F Y， et al. Silencing long noncoding RNA LINC01133 suppresses pancreatic cancer through regulation of microRNA-1299-dependent IGF2BP3［J］. J Biochem Mol Toxicol， 2024， 38（1）： e23534.
[61]	XU C， WANG S M， SUN Y. The role of KRT7 in metastasis and prognosis of pancreatic cancer［J］. Cancer Cell Int， 2024， 24（1）： 321.
[62]	GUO Z Y， ZHANG X， LIN C J， et al. METTL3-IGF2BP3-axis mediates the proliferation and migration of pancreatic cancer by regulating spermine synthase m⁶A modification［J］. Front Oncol， 2022， 12： 962204.
[63]	HE Y， LIU Y X， WU D K， et al. Linc-UROD stabilizes ENO1 and PKM to strengthen glycolysis， proliferation and migration of pancreatic cancer cells［J］. Transl Oncol， 2023， 27： 101583.
[64]	Zhang S， Lai T， Su X， et al. Linc00662 m⁶A promotes the progression and metastasis of pancreatic cancer by activating focal adhesion through the GTF2B-ITGA1-FAK pathway. Am J Cancer Res，2023，13（5）：1718-1743.
[65]	JIN W W， YAO Y R， FU Y H， et al. WTAP/IGF2BP3-mediated GBE1 expression accelerates the proliferation and enhances stemness in pancreatic cancer cells via upregulating c-Myc［J］. Cell Mol Biol Lett， 2024， 29（1）： 97.
[66]	ZHOU Y H， HUANG T T， SIU H L， et al. IGF2BP3 functions as a potential oncogene and is a crucial target of miR-34a in gastric carcinogenesis［J］. Mol Cancer， 2017， 16（1）： 77.
[67]	YANG F F， MA Q， HUANG B， et al. CircNFATC3 promotes the proliferation of gastric cancer through binding to IGF2BP3 and restricting its ubiquitination to enhance CCND1 mRNA stability［J］. J Transl Med， 2023， 21（1）： 402.
[68]	YU T， RAN L Y， ZHAO H W， et al. Circular RNA circ-TNPO3 suppresses metastasis of GC by acting as a protein decoy for IGF2BP3 to regulate the expression of MYC and SNAIL［J］. Mol Ther Nucleic Acids， 2021， 26： 649-664.
[69]	HU Y Y， GONG C L， LI Z B， et al. Demethylase ALKBH5 suppresses invasion of gastric cancer via PKMYT1 m⁶A modification［J］. Mol Cancer， 2022， 21（1）： 34.
[70]	WANG Q， CHEN C， DING Q Q， et al. METTL3-mediated m⁶A modification of HDGF mRNA promotes gastric cancer progression and has prognostic significance［J］. Gut， 2020， 69（7）： 1193-1205.
[71]	LIN K， LIN X F， LUO F. IGF2BP3 boosts lactate generation to accelerate gastric cancer immune evasion［J］. Apoptosis， 2024， 29（11）： 2147-2160.
[72]	GE L C， RUI Y L， WANG C， et al. The RNA m⁶A reader IGF2BP3 regulates NFAT1/IRF1 axis-mediated anti-tumor activity in gastric cancer［J］. Cell Death Dis， 2024， 15： 192.
[73]	YIFANG M， XINGYU J， PENG G，et al.ZXDC enhances cervical cancer metastasis through IGF2BP3-mediated activation of RhoA/ROCK signaling［J］.iScience，2023，26（8）： 107447.
[74]	ZHU J M， HAN S C. Downregulation of LncRNA DARS-AS1 inhibits the tumorigenesis of cervical cancer via inhibition of IGF2BP3［J］. OncoTargets Ther， 2021， 14： 1331-1340.
[75]	ZHOU T T， XIAO Z Y， LU J， et al. IGF2BP3-mediated regulation of GLS and GLUD1 gene expression promotes treg-induced immune escape in human cervical cancer［J］. Am J Cancer Res， 2023， 13（11）：5289-5305.
[76]	ZHANG Y， WANG D， WU D， et al. Long noncoding RNA KCNMB2-AS1 stabilized by N⁶-methyladenosine modification promotes cervical cancer growth through acting as a competing endogenous RNA［J］. Cell Transplant， 2020， 29： 096368972096438.
[77]	TIAN Q Q， HUANG J Q， ZHANG Q， et al. N6-methyladenosine methylation on FSCN1 mediated by METTL14/IGF2BP3 contributes to human papillomavirus type 16-infected cervical squamous cell carcinoma［J］. Clin Exp Pharmacol Physiol， 2024， 51（6）： e13864.
[78]	LIU H T， ZHAO Y， WANG H C， et al. METTL3-mediated m⁶A methylation of SLC38A1 stimulates cervical cancer growth［J］. Biochem Biophys Res Commun， 2024， 716： 150039.
[79]	ZHANG N， SHEN Y， LI H， et al. The m6A reader IGF2BP3 promotes acute myeloid leukemia progression by enhancing RCC2 stability［J］. Exp Mol Med， 2022， 54（2）： 194-205.
[80]	LIU J P， JIANG X， ZOU A L， et al. circIGHG-induced epithelial-to-mesenchymal transition promotes oral squamous cell carcinoma progression via miR-142-5p/IGF2BP3 signaling［J］. Cancer Res， 2021， 81（2）： 344-355.
[81]	DU M Y， PENG Y， LI Y， et al. MYC-activated RNA N6-methyladenosine reader IGF2BP3 promotes cell proliferation and metastasis in nasopharyngeal carcinoma［J］. Cell Death Discov， 2022， 8： 53.
[82]	LIU S L， LI H F， ZHU Y D， et al. LncRNA MNX1-AS1 sustains inactivation of Hippo pathway through a positive feedback loop with USP16/IGF2BP3 axis in gallbladder cancer［J］. Cancer Lett， 2022， 547： 215862.
[83]	HUANG W， LI Y Y， ZHANG C， et al. IGF2BP3 facilitates cell proliferation and tumorigenesis via modulation of JAK/STAT signalling pathway in human bladder cancer［J］. J Cell Mol Med， 2020， 24（23）： 13949-13960.
[84]	GU Y M， NIU S X， WANG Y， et al. DMDRMR-mediated regulation of m⁶A-modified CDK4 by m⁶A reader IGF2BP3 drives ccRCC progression［J］. Cancer Res， 2021， 81（4）： 923-934.

Research progress in biological roles of m⁶A reader protein IGF2BP3 in development and progression of malignant tumor

RichHTML

PDF (PC)

Like

Knowledge

Abstract

Cite this article

share this article

Figures/Tables 3

References 84

Related Articles 15

Metrics

Comments

Recommended 0

[1]	Lina ZHANG,Zhesi MENG,Long BA,Jun MENG. Research progress in relationship between cell division cycle protein 6 and occurrence and development of tumor [J]. Journal of Jilin University(Medicine Edition), 2026, 52(3): 847-853.
[2]	Yang YU,Sheyu YE,Kexin WEI,Zhicheng WANG. Research progress in formation mechanism of tumor radioresistance and inhibitory effect of low-dose radiotherapy combination with novel sensitization strategies on tumor radioresistance [J]. Journal of Jilin University(Medicine Edition), 2026, 52(3): 872-880.
[3]	Xiqian ZHANG,Zhibo DANG,Yunan DU,Pei WU,Hang XIE,Gaofeng TAN. Inhibitory effect of Chaiqi Yigan formula on malignant biological behaviors of liver cancer HepG2 cells by regulating macrophage polarization [J]. Journal of Jilin University(Medicine Edition), 2026, 52(2): 398-409.
[4]	Xun LU,Chengxin MA,Jianan YANG,Xinxin GUO,Xiaobei XIE,Binghai ZHAO,Hongzhi LI. Research progress in mechanism of podocyte injury and its potential therapeutic strategies for diabetic nephropathy [J]. Journal of Jilin University(Medicine Edition), 2025, 51(5): 1415-1422.
[5]	Jia YANG,Lingling TONG,Jinshu MA,Huafeng GENG. Misdiagnosis of ovarian sclerosing stromal tumor as malignant tumor: A case report and literature review [J]. Journal of Jilin University(Medicine Edition), 2025, 51(4): 1115-1120.
[6]	Xialing HUANG,Dandan ZHANG,Xuemei ZHANG. Analysis on relationship between methylation of MSX1 gene and clinical pathological features and prognosis of patients with cervical cancer [J]. Journal of Jilin University(Medicine Edition), 2025, 51(3): 749-756.
[7]	Xinyi YU,Zhifang JIA,Yuzheng ZHANG,Yuchen PAN,Yangyu ZHANG,Yanhua WU,Donghui CAO,Jing JIANG. Analysis on distribution and trend of malignant tumor incidence and mortality in Dehui City and Yanji City in Jilin Province from 2009 to 2016 [J]. Journal of Jilin University(Medicine Edition), 2025, 51(3): 797-806.
[8]	Luyao WANG,Chenxi ZHAO,Wanze ZHANG,Linlin LIU. Second primary tracheal adenoid cystic carcinoma:A case report and literature review [J]. Journal of Jilin University(Medicine Edition), 2025, 51(1): 215-221.
[9]	Honghong LI,Na YU,Minghao SHI,Ying SUN,Yao LI,Zhongjun SHEN,Xiaoyi LIU,Liyan ZHAO. Predictive value of new thrombotic risk assessment model for venous thromboembolism in patients with malignant tumors [J]. Journal of Jilin University(Medicine Edition), 2024, 50(5): 1390-1399.
[10]	Zhaohui LIAO,Zhengyuan XIE. Research progress in molecular mechanism of hepatic fibrosis and related therapeutic targets [J]. Journal of Jilin University(Medicine Edition), 2024, 50(5): 1450-1456.
[11]	Haiyao PANG,Jun MENG. Research progress in relationship between 14-3-3ɛ protein and occurrence and development of tumor [J]. Journal of Jilin University(Medicine Edition), 2024, 50(2): 572-578.
[12]	Yihan WANG,Yidan WANG,Hetong HUI,Xinyuan FAN,Tianqi WANG,Wei XIA,Limei LIU. Detection of promoter methylation levels of Wnt5A and LINE-1 in serum during extramedullary infiltration in acute lymphoblastic leukemia transplanted tumor model mice and its significance [J]. Journal of Jilin University(Medicine Edition), 2022, 48(2): 284-290.
[13]	Min WANG,Pengyue YU,Yan WANG,Yanke SONG,Yao LI,Ying SUN,Liyan ZHAO. Evaluation values of peripheral blood coagulation indexes, platelet count and NLR in coagulation state in patients with malignant tumors before treatment [J]. Journal of Jilin University(Medicine Edition), 2022, 48(1): 203-210.
[14]	Cong WANG, Xiu GUO, Hao CHI, Jie ZHANG, Mingyu XU, Chunling DONG. Application values of simplified Wells score, revised Geneva score and D-dimer level in diagnosis of malignant tumor complicated with pulmonary thromboembolism [J]. Journal of Jilin University(Medicine Edition), 2021, 47(3): 707-713.
[15]	SUN Munan, FANG Yanqiu, LIU Lei, MA Yinfu, WEI Haifeng, TAN Yan. Detection of Th9 cells in peripheral blood of patients with small cell lung cancer and its clinical significance [J]. Journal of Jilin University Medicine Edition, 2016, 42(03): 561-564.

Research progress in biological roles of m6A reader protein IGF2BP3 in development and progression of malignant tumor

RichHTML

PDF (PC)

Like

Knowledge

Abstract

Cite this article

share this article

Figures/Tables 3

References 84

Related Articles 15

Metrics

Comments

Recommended 0

Research progress in biological roles of m⁶A reader protein IGF2BP3 in development and progression of malignant tumor